Table 1.
Summary of clinicopathological data and results of molecular investigation of non melanoma skin cancer
| References | Tumor type | HPyV6 DNA | Detection Methode | HPyV6 IHC 6V32 | HPyV6-FISH | Clinical Data |
|---|---|---|---|---|---|---|
| Schowalter et al. [14] | NS (n = 35) | 14,3 % | DNA-PCR | NA | NA | IC |
| Ser (n = 65) | 69 % | VP1 ELISA | NA | |||
| Duncavage et al. [22] | MCC (n = 28) | 3,5 % | rt-PCR | NA | NA | NA |
| Schrama et al. [24] | SCC (n = 21) | 38 % | qPCR | NA | NA | NA |
| BCC (n = 18) | 5,5 % | |||||
| MCC (n = 20) | 10 % | |||||
| Scola et al. [25] | SCC (n = 52) | 4 % | rt-PCR | NA | NA | IC |
| BCC (n = 41) | 7 % | |||||
| KA (n = 42) | 5 % | |||||
| Imajoh et al. [23] | NS (n = 34) | 8,8 % | rt-PCR | NA | NA | NA |
| SCC (n = 63) | 3,2 % | |||||
| BCC (n = 50) | 2 % | |||||
| Nicol et al. [19] | Ser | 37,5 % pos. (age 1–4) | VP1 ELISA | NA | NA | IC |
| 61,8 % pos. (age 15–19) | ||||||
| 67,1 % pos (age 30–38) | ||||||
| 98,2 % pos. (age 80+) | ||||||
| Schrama et al. [28] | KA (n = 4) | 25 % | rt-PCR | KA 1/4 (25 %) | NA | IS |
IS immunosuppressed, IC immunocompetent, PCR polymerase chain reaction, IHC immunohistochemistry, FISH fluorescence in situ hybridisation, rt-PCR real time PCR, qPCR quantitative PCR, ELISA enzyme-linked immunosorbent assay, HPyV6 human polyomavirus 6, NS normal skin, Ser serum, SCC squamous cell carcinoma, BCC basal cell carcinoma, KA keratoacanthoma, MCC Merkel cell carcinoma, NA not applicable